Tyk2 Active Human Recombinant Protein
- Known as:
- Tyk2 Active Human Recombinant Protein
- Catalog number:
- 40285
- Product Quantity:
- 10 µg
- Category:
- -
- Supplier:
- Biotech support group
- Gene target:
- Tyk2 Active Human Recombinant Protein
Related genes to: Tyk2 Active Human Recombinant Protein
- Gene:
- TYK2 NIH gene
- Name:
- tyrosine kinase 2
- Previous symbol:
- -
- Synonyms:
- JTK1
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-09-10
- Date modifiied:
- 2019-04-23
Related products to: Tyk2 Active Human Recombinant Protein
Related articles to: Tyk2 Active Human Recombinant Protein
- Prostate cancer remains a major global health burden for men, with its incidence and mortality steadily rising. Thyroid hormones, critical regulators of metabolism and cell growth, have been implicated in tumorigenesis, yet their specific role in prostate cancer risk remains unclear. This study systematically investigates the relationship between thyroid hormones and prostate cancer using multidimensional approaches. - Source: PubMed
Publication date: 2025/05/21
Wu JinhaiChen SianXu RanChen YanfeiGuo JiadinLi JingZeng XihengWang BinZhu Xuejin - Deucravacitinib is a highly selective allosteric inhibitor of protein tyrosine kinase 2 (TYK2). It targets the Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway. Despite its selectivity, the structural basis for its inhibition mechanism remains poorly understood. Here, we analyze available atomic resolution structures relevant to the JAK-STAT pathway to investigate the TYK2 inhibition mechanism. Our computational analysis suggests a mechanistic hypothesis for the relatively rapid interferon-induced gene expression mediated by TYK2 compared to other cytokine pathways. We find that deucravacitinib and other TYK2-specific allosteric drugs inhibit TYK2 kinase in three distinct states: an autoinhibited state and two activated states. The activated states are involved in autophosphorylation and the phosphorylation of downstream proteins. In the autoinhibited state, deucravacitinib binds to the TYK2 pseudokinase domain. This binding restricts essential dynamics of the TYK2 kinase domain needed for kinase activity. Additionally, deucravacitinib competes with ATP binding in the pseudokinase domain. This competitive binding directly prevents the formation of the active TYK2 state through steric clashes. - Source: PubMed
Publication date: 2025/05/14
Wang JiminLomakin Ivan BBatista Victor SBunick Christopher G - This study aimed to analyze the effects of naphthoquinone scaffold-derived compounds on head and neck squamous cell carcinoma (HNSCC) using network pharmacology and molecular docking. - Source: PubMed
Publication date: 2025/04/15
Liao YihengQiu LinTao AnqiLi Cuiying - Psoriasis treatments that provide rapid and extensive itch relief, lesion clearance are inadequate. - Source: PubMed
Publication date: 2025/05/14
Chen Jia-QiZheng MinYin Wen-HaoWang PingShi Xiao-WeiLei Tie-ChiLi Zhi-MingPan MengShi Yu-LingLi Yu-ZhenLiang CongxinMan Xiao-Yong - Tyrosine protein-kinase 2 (TYK2) mediates inflammatory signalling through multiple cytokines, including interferon-α (IFNα), interleukin (IL)-12, and IL-23. TYK2 missense mutations protect against type 1 diabetes (T1D), and inhibition of TYK2 shows promise in other autoimmune conditions. - Source: PubMed
Publication date: 2025/05/02
Syed FarooqBallew OliviaLee Chih-ChunRana JyotiKrishnan PreethiCastela AngelaWeaver Staci AChalasani Namratha ShivaniThomaidou Sofia FDemine StephaneChang GarrickCoomans de Brachène AlexandraAlvelos Maria InesVazquez Eugenia MartinMarselli LorellaOrr KaraFelton Jamie LLiu JingKaddis John SMarchetti PieroZaldumbide ArnaudScheuner DonalynEizirik Decio LEvans-Molina Carmella